Kit for the prognosis of colorectal cancer

Patent metadata

Field	Value
Publication number	US-10072300-B2
Application number	US-201414893394-A
Country	US
Kind code	B2
Filing date	May 20, 2014
Priority date	May 21, 2013
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

A kit for the prognosis of colorectal cancer, which includes reagents related in detecting the expression level of any one or more genes of the following five genes: BST1, as shown in SEQ ID NO:1; MGST1, as shown in SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO:11 or 12; RCAN3, as shown in SEQ ID NO:13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO:23 or 24. The reagents are used to detect the expression level of any one or more of the above five genes in the preparation of a kit for the prognosis of colorectal cancer. The kit can be used to perform precise prognosis for a patient suffering from colorectal cancer, and has good clinical application prospects.

First claim

The invention claimed is:

1. A method for detecting gene expression, comprising:
obtaining a blood sample collected from a human having colorectal cancer; and
detecting expression levels of the BST1, MGST1, HP, RCAN3, and SRA1 genes from the blood sample by hybridization, amplification, or sequencing wherein detecting the expression levels comprises detecting RNA transcripts transcribed from the genes, cDNAs complementary to the RNA transcripts, or cRNAs complementary to the cDNAs, wherein:
the BST1 gene has the nucleotide sequence shown in SEQ ID NO: 1;
the MGST1 gene has the nucleotide sequence shown in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, or 10;
the HP gene has the nucleotide sequence shown in SEQ ID NO: 11 or 12;
the RCAN3 gene has the nucleotide sequence shown in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22; and
the SRA1 gene has the nucleotide sequence shown in SEQ ID NO: 23 or 24.

2. The method according to claim 1 , wherein detecting the expression levels comprises detecting the RNA transcripts.

3. The method according to claim 1 , wherein detecting the expression levels comprises detecting the cDNAs.

4. The method according to claim 1 , wherein detecting the expression levels comprises detecting the cRNAs.

5. The method according to claim 1 , wherein detecting the expression levels comprises performing a reverse-transcription polymerase chain reaction.

6. The method according to claim 1 , wherein detecting the expression levels comprises using oligonucleotides.

7. The method according to claim 1 , wherein detecting the expression levels comprises using primers.

8. The method according to claim 1 , wherein detecting the expression levels comprises using hybridization probes.

9. The method according to claim 1 , wherein detecting the expression levels comprises using hybridization probes and primers.

10. The method according to claim 1 , wherein detecting the expression levels comprises using oligonucleotides that hybridize with the RNA transcripts.

11. The method according to claim 1 , wherein detecting the expression levels comprises using oligonucleotides that hybridize with the cDNAs.

12. The method according to claim 1 , wherein detecting the expression levels comprises:
amplifying the RNA transcripts to obtain amplified products; and
detecting the amounts of the amplified products using primers.

13. The method according to claim 1 , wherein detecting the expression levels comprises:
amplifying the RNA transcripts to obtain the cDNAs;
hybridizing probes to the cDNAs to obtain hybridization products; and
detecting the amounts of the hybridization products.

14. The method according to claim 1 , wherein detecting the expression levels comprises using oligonucleotides comprising the nucleotide sequences shown in SEQ ID NOs: 25-34.

15. A method for prognosis of colorectal cancer, comprising:
obtaining a blood sample collected from a patient having colorectal cancer;
detecting expression levels of the BST1, MGST1, HP, RCAN3, and SRA1 genes from the blood sample by hybridization, amplification, or sequencing wherein detecting the expression levels comprises detecting RNA transcripts transcribed from the genes, cDNAs complementary to the RNA transcripts, or cRNAs complementary to the cDNAs;
inputting the expression levels of the genes into a support vector machine model to calculate a prognosis index; and
determining the prognosis of the patient based on the prognosis index, wherein:
the BST1 gene has the nucleotide sequence shown in SEQ ID NO: 1;
the MGST1 gene has the nucleotide sequence shown in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, or 10;
the HP gene has the nucleotide sequence shown in SEQ ID NO: 11 or 12;
the RCAN3 gene has the nucleotide sequence shown in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22; and
the SRA1 gene has the nucleotide sequence shown in SEQ ID NO: 23 or 24.

16. The method according to claim 15 , wherein detecting the expression levels comprises detecting the RNA transcripts.

17. The method according to claim 15 , wherein detecting the expression levels comprises detecting the cDNAs.

18. The method according to claim 15 , wherein detecting the expression levels comprises detecting the cRNAs.

19. The method according to claim 15 , wherein detecting the expression levels comprises performing a reverse-transcription polymerase chain reaction.

20. The method according to claim 15 , wherein detecting the expression levels comprises using oligonucleotides.

21. The method according to claim 15 , wherein detecting the expression levels comprises using primers.

22. The method according to claim 15 , wherein detecting the expression levels comprises using hybridization probes.

23. The method according to claim 15 , wherein detecting the expression levels comprises using hybridization probes and primers.

24. The method according to claim 15 , wherein detecting the expression levels comprises using oligonucleotides that hybridize with the RNA transcripts.

25. The method according to claim 15 , wherein detecting the expression levels comprises using oligonucleotides that hybridize with the cDNAs.

26. The method according to claim 15 , wherein detecting the expression levels comprises:
amplifying the RNA transcripts to obtain amplified products; and
detecting the amounts of the amplified products using primers.

27. The method according to claim 15 , wherein detecting the expression levels comprises:
amplifying the RNA transcripts to obtain the cDNAs;
hybridizing probes to the cDNAs to obtain hybridization products; and
detecting the amounts of the hybridization products.

28. The method according to claim 15 , wherein detecting the expression levels comprises using oligonucleotides comprising the nucleotide sequences shown in SEQ ID NOs: 25-34.

Assignees

• Biomerieux Sa
• Biomerieux Sa

Inventors

• Meng Xia
• Xu Qinghua
• Ye Xun
• Liu Fang
• Wu Fei

Classifications

• G01N33/57535

  of the large intestine, e.g. colon, rectum or anus · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title